{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:09:15Z","timestamp":1787317755351,"version":"build-2736575974"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.vhri.2025.101555","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T23:20:45Z","timestamp":1765408845000},"page":"101555","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cost-Effectiveness of Pembrolizumab as First-Line Therapy for Advanced Colorectal Cancer With High Microsatellite Instability or Mismatched Repair Deficiency in Japan"],"prefix":"10.1016","volume":"54","author":[{"given":"Seiya","family":"Taniguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Moriwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kojiro","family":"Shimozuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vhri.2025.101555_bib5","series-title":"JSCCR Guidelines 2024 for the Treatment of Colorectal Cancer","year":"2024"},{"key":"10.1016\/j.vhri.2025.101555_bib6","series-title":"Clinical Oncology Update-Essentials for Medical Oncologists","year":"2021"},{"issue":"3","key":"10.1016\/j.vhri.2025.101555_bib7","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/cas.14798","article-title":"Real-world data on microsatellite instability status in various unresectable or metastatic solid tumors","volume":"112","author":"Akagi","year":"2021","journal-title":"Cancer Sci"},{"issue":"3","key":"10.1016\/j.vhri.2025.101555_bib9","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.annonc.2024.11.012","article-title":"Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study","volume":"36","author":"Andr\u00e9","year":"2025","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.vhri.2025.101555_bib10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/13696998.2022.2043634","article-title":"Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H\/dMMR colorectal cancer in the United States","volume":"25","author":"Aguiar-Ib\u00e1\u00f1ez","year":"2023","journal-title":"J Med Econ"},{"issue":"8","key":"10.1016\/j.vhri.2025.101555_bib11","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1080\/1120009X.2022.2162220","article-title":"Cost-effectiveness analysis of pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer","volume":"35","author":"Liu","year":"2023","journal-title":"J Chemother"},{"issue":"1","key":"10.1016\/j.vhri.2025.101555_bib12","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1186\/s12913-023-10037-1","volume":"23","author":"Zhu","year":"2023","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.vhri.2025.101555_bib13","series-title":"Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency. National Institute for Health and Care Excellence: Technology Appraisals","first-page":"709","year":"2021"},{"issue":"3","key":"10.1016\/j.vhri.2025.101555_bib15","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jval.2016.08.726","article-title":"Development of an official guideline for the economic evaluation of drugs\/medical devices in Japan","volume":"20","author":"Shiroiwa","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2025.101555_bib16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109925004819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109925004819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T15:36:30Z","timestamp":1783438590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109925004819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":10,"alternative-id":["S2212109925004819"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2025.101555","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Pembrolizumab as First-Line Therapy for Advanced Colorectal Cancer With High Microsatellite Instability or Mismatched Repair Deficiency in Japan","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2025.101555","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101555"}}